BEST UNLIMITED TURBO LONG CERTIFICATE - AMGEN | Market Closed - Euronext Paris 10:00:00 28/06/2024 pm IST | ||
| 2.828 EUR | -2.25% |
|
| Current month | +12.44% | ||
| 1 month | +20.58% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
AMGEN INC.
| Date | Price | Change |
|---|---|---|
| 28/24/28 | 2.801 | -3.18% |
| 27/24/27 | 2.893 | -2.16% |
| 26/24/26 | 2.957 | -7.94% |
| 25/24/25 | 3.212 | +8.99% |
| 24/24/24 | 2.947 | +8.23% |
Real-time Euronext Paris
Last update June 28, 2024 at 10:00 pm IST
More quotesStatic data
| Product type | Knock-Out without Stop Loss |
|---|---|
| Buy / Sell | CALL |
| Underlying | AMGEN INC. |
| Issuer | 
Société Générale
|
| TM18S | |
| ISIN | DE000SU6TX25 |
| Date issued | 10/01/2024 |
| Strike | 254.6 $ |
| Maturity | Unlimited |
| Parity | 20 : 1 |
| Emission price | 3.1 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 3.913 € |
|---|---|
| Lowest since issue | 0.582 € |
Company Profile
Amgen Inc. is one of the world's leading biotechnology groups. Net sales break down by source of revenue as follows:
- drug sales (94.2%): drugs for treating cancer, metabolic disorders, bone diseases, renal failure, hemophilia, etc.;
- other (5.8%): primarily royalties.
The United States account for 70.3% of net sales.
Sector
-
Consensus: Amgen Inc.
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
30
Last Close Price
312.4
USD
Average target price
316.4
USD
Spread / Average Target
+1.28%
- Stock Market
- Certificates
- TM18S Certificat
